Business Context and Reporting Period
This Form 8-K filing by Alnylam Pharmaceuticals, Inc. (ALNY) reports corporate governance changes effective February 26, 2020, with the report filed on February 27, 2020. The filing details the resignation of a director and the election of a new director to the Board of Directors.
Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on personnel changes and director compensation arrangements.
Material Changes
- Resignation: Paul R. Schimmel, Ph.D., resigned from the Board effective at the end of his term at the 2020 annual meeting (May 6, 2020). The resignation was not due to any disagreement with the Company. He will continue serving on the Scientific Advisory Board.
- Appointment: Olivier Brandicourt, M.D., was elected to fill a newly created vacancy, expanding the Board from eleven to twelve members effective March 2, 2020. He serves as a Class II director with a term expiring in 2021.
- Board Size Adjustment: The Board approved a reduction in size from twelve back to eleven members effective upon Dr. Schimmel's resignation.
Guidance, Outlook, and Compensation
The filing outlines the compensatory arrangements for the newly elected director, Dr. Brandicourt:
- Cash Fee: Annual cash fee of $55,000.
- Initial Stock Option: Grant date fair value of $600,000, vesting ratably in three annual installments starting one year after the grant date.
- Future Annual Awards: Beginning in 2021, eligible for annual stock options with a grant date fair value of $400,000, vesting in full one year after the grant date.
- Other: Reimbursement for reasonable travel and related expenses; entry into a standard indemnification agreement.
Dr. Brandicourt is noted as the former CEO of Sanofi Genzyme, with whom Alnylam has an amended collaboration agreement detailed in the Company's 2019 Form 10-K.
Key Facts for Investor Verification
- Confirm the effective dates of the Board composition changes (March 2, 2020, for appointment; May 6, 2020, for resignation).
- Review the Company's 2019 Form 10-K for details on the strategic alliance with Sanofi Genzyme, given the new director's prior role there.
- Verify the total dilution impact of the $600,000 initial stock option grant based on the share price at the time of grant.